Affimed Therapeutics appoints Jens-Peter Marschner as chief medical officer

German privately-owned biopharmaceutical company Affimed Therapeutics has appointed Jens-Peter Marschner as Chief Medical Officer.

Dr Marschner recently joined Affimed from Germany’s Merck KGaA (MRK: DE). He has 18 years of professional experience in clinical development with a focus on biological compounds. Working in several pharmaceutical companies, he has been responsible for conducting clinical trials in all phases of development. He led the clinical development team of Erbitux (cetuximab), a monoclonal antibody to treat colorectal cancer, which was successfully launched in 2004. During his career he has also been responsible for the early and late stage development of cancer immune therapies. As VP Global Medical Affairs at Merck KGaA Dr Marschner gained comprehensive experience in market-related medical and scientific affairs, primarily in the field of oncology.

Adi Hoess, chief executive of Affimed, said: "I am delighted to welcome Jens-Peter as a key member of the Executive Management Board. His expert knowledge and experience in oncology drug development and management adds significantly to our company and our future. Jens-Peter's expertise will ensure that Affimed continues to build on its leadership in the development of bispecific immunotherapies."